IBA SA : IBA to install Africa's first proton therapy center
28 Avril 2017 - 07:00AM
IBA to install
Africa's first proton therapy center
Contract signed
with Children's Cancer Hospital Foundation Egypt to install a
Proteus®ONE solution
in Cairo, Egypt
Louvain-La-Neuve,
Belgium, 28 April 2017 - IBA (Ion Beam Applications S.A.,
EURONEXT), the world's leading provider of proton therapy solutions
for the treatment of cancer, today announces that it has signed a
contract with the Children's Cancer Hospital Foundation Egypt
(CCHF), a leading NGO in Egypt, to install a Proteus®ONE* compact
proton therapy solution at Hospital 57357 (CCHE) in Cairo.
This contract covers the delivery
of a Proteus®ONE solution,
including the latest generation Pencil Beam Scanning, isocenter
volumetric imaging (Cone Beam CT) capabilities and a long-term
maintenance agreement. The hospital plans to start treating
patients by 2020. The typical end-user price for a Proteus®ONE system with a maintenance contract is between EUR
35 and 40 million. This will be IBA's 19th installation
of the compact single-room proton therapy solution.
Olivier Legrain,
Chief Executive Officer of IBA, commented: "Due to the precise
nature of its delivery, proton therapy is particularly appropriate
for the treatment of children. Children with tumors in the brain,
head, neck, spinal cord, lungs, etc., can benefit from this
treatment because protons deposit the majority of their energy
within a controlled zone while limiting the impact on healthy
tissue that surrounds the tumor. The Children's Cancer Hospital
Foundation Egypt and Hospital 57357's philosophy and ambition of
providing children with cancer access to the most advanced
radiation therapy technology is creditable; we're pleased to
partner with CCHF and CCHE and to be installing the first
proton therapy solution in Africa."
Prof Sherif
Abouelnaga, Chief Executive Officer of Children's Cancer Hospital
Egypt 57357, commented: "Our mission is to provide the best
comprehensive family-centered quality care and a chance to cure all
children with cancer, free of charge and without discrimination. We
are excited to partner with IBA to bring the world's leading proton
beam therapy equipment to cancer patients in Egypt for the first
time. Our vision and ambition is to become the center of excellence
in radiotherapy for Africa and the Middle East."
***ENDS***
About Proteus®ONE
Proteus®ONE is the
compact intensity modulated proton therapy (IMPT) solution from
IBA. It benefits from the latest technologies developed with
renowned clinical institutions. Proteus®ONE is
smaller, more affordable, easier to install and to operate. It is
ultimately easier to finance, making this advanced radiation
therapy modality available to more institutions and patients
worldwide.
* Proteus®ONE is the
brand name of Proteus®235
About IBA
IBA (Ion Beam Applications S.A.) is a global medical technology
company focused on bringing integrated and innovative solutions for
the diagnosis and treatment of cancer. The company is the worldwide
technology leader in the field of proton therapy, considered to be
the most advanced form of radiation therapy available today. IBA's
proton therapy solutions are flexible and adaptable, allowing
customers to choose from universal full-scale proton therapy
centers as well as compact, single room solutions. In addition, IBA
also has a radiation dosimetry business and develops particle
accelerators for the medical world and industry. Headquartered in
Belgium and employing about 1,500 people worldwide, IBA has
installed systems across the world.
IBA is listed on the pan-European
stock exchange NYSE EURONEXT (IBA: Reuters IBAB.BR and Bloomberg
IBAB.BB).
More information can be found at: www.iba-worldwide.com
About Children's Cancer Hospital
Egypt 57357
The Children's Cancer Hospital Egypt 57357 (CCHE) widely known as
"Hospital 57357" is the largest pediatric oncology hospital in the
world with a present capacity of 320 beds. The CCHE is a unique
humanitarian project as it was built and is being sustained by
donations. In operation since July, 2007, it has quickly become
recognized as a leader not only on the national level but also
globally; specially in the MENA Region and Africa. The Hospital is
providing a new level of world quality healthcare where all
children are treated free of charge without discrimination.
Utilizing multi-sector cooperation, CCHE is a model of a
sustainable healthcare system in the developing world that can be
duplicated elsewhere.
The hospital is treating an
estimated 45% of Egypt's pediatric cancer cases (number of
cases annually) and improving cure rates from less than 20-40% to
almost 75%. CCHE's aim is to be able to accept 80 to 90% of annual
new cases in Egypt while remaining committed to referrals from
Africa and other Arab countries. To achieve this, we have embarked
on an important capacity and program expansion project by
transitioning from a Hospital to a Health Sciences Campus. Besides
doubling its capacity, the new campus includes a Healthcare
Sciences Academy to train a new generation of healthcare
professionals capable of being change agents in their communities
and the latest, a larger out-patient facility to house a cutting
edge technology in radiation therapy, the proton therapy, and an
advanced research center
After 10 years of operations, the 57357 institution has set a
new era of healthcare in Egypt as well as new standards for
charity. It has demonstrated internally and to the outside
world its potential as a national pride project, a vessel for
change, a holder of true medicine and technology and a financially
sound and reliable endeavor.
More information can be found at: www.57357.org
For further information, please
contact:
IBA
Jean-Marc Bothy
Chief Strategy Officer
Soumya
Chandramouli
Chief Financial Officer
Bernard Dandoy
Investor Relations
+32 10 475 890
Investorrelations@iba-group.com
Thomas
Ralet
Vice-President Corporate Communication
+32 10 475 890
communication@iba-group.com
For media and
investor enquiries:
Consilium
Strategic Communications
Amber Fennell, Matthew Neal, Ivar Milligan
+44 (0) 20 3709 5700
IBA@consilium-comms.com
28-04-17-IBA-PR-Cairo_EN_final
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: IBA SA via Globenewswire
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Fév 2024 à Mar 2024
Ion Beam Applications (EU:IBAB)
Graphique Historique de l'Action
De Mar 2023 à Mar 2024